FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Giorgio Parmiani

Research Profile

Disorders

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Mouse

Procedures

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Vincenzo Russo; Monica Salomoni; mario santinami; Catia Traversari; Claudio Bordignon; Fabio Ciceri; Pierre G Coulie; Roberto Crocchiolo; Ferruccio Fazio; Matteo Del Fiacco; Annabella Di Florio; Raffaella Fontana; Corrado Gallo-Stampino; Luigi Gianolli; Raffaella Greco; Antonio Lambiase; Francesca Lunghi; Daniela Maggioni; Michele Maio; Alfonso Marchianò; Alessandro Del Maschio; Santo Raffaele Mercuri; Sylvain Mukenge; Roberto Nicoletti; Giorgio Parmiani; Roberto Patuzzo; Lorenzo Pilla; Gianluigi Rigamonti; Licia Rivoltini; Marco Bregni
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
Chiara Camisaschi; Chiara Casati; Philipp Beckhove; Valeria Beretta; Emilio Berti; Vanna Chiarion-Sileni; Agata Cova; Paola Filipazzi; Michele Maio; Andrea Maurichi; Giorgio Parmiani; Roberto Patuzzo; Lorenzo Pilla; Licia Rivoltini; mario santinami; Marcella Tazzari; Gabrina Tragni; Ludmila Umansky; Viktor Umansky; Barbara Vergani; Antonello Villa; Chiara Castelli
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Rossana Tallerico; Luca Tirinato; Matilde Todaro; Enzo Di Fabrizio; Simone Di Franco; Francesco Dieli; Cinzia Garofalo; Klas Kärre; Rosanna La Rocca; Cristina Maccalli; Ofer Mandelboim; Alessandro Moretta; Camillo Palmieri; Pradeepa N Pangigadde; Giorgio Parmiani; Rosa Sottile; Giorgio Stassi; Ennio Carbone
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Giorgio Parmiani (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Vincenzo Russo; Monica Salomoni; mario santinami; Catia Traversari; Claudio Bordignon; Fabio Ciceri; Pierre G Coulie; Roberto Crocchiolo; Ferruccio Fazio; Matteo Del Fiacco; Annabella Di Florio; Raffaella Fontana; Corrado Gallo-Stampino; Luigi Gianolli; Raffaella Greco; Antonio Lambiase; Francesca Lunghi; Daniela Maggioni; Michele Maio; Alfonso Marchianò; Alessandro Del Maschio; Santo Raffaele Mercuri; Sylvain Mukenge; Roberto Nicoletti; Giorgio Parmiani; Roberto Patuzzo; Lorenzo Pilla; Gianluigi Rigamonti; Licia Rivoltini; Marco Bregni
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
International journal of cancer. Journal international du cancer 2013;132(11):2557-66.
2013: Chiara Camisaschi; Chiara Casati; Philipp Beckhove; Valeria Beretta; Emilio Berti; Vanna Chiarion-Sileni; Agata Cova; Paola Filipazzi; Michele Maio; Andrea Maurichi; Giorgio Parmiani; Roberto Patuzzo; Lorenzo Pilla; Licia Rivoltini; mario santinami; Marcella Tazzari; Gabrina Tragni; Ludmila Umansky; Viktor Umansky; Barbara Vergani; Antonello Villa; Chiara Castelli
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Cancer immunology, immunotherapy : CII 2013;62(5):897-908.
2013: Rossana Tallerico; Luca Tirinato; Matilde Todaro; Enzo Di Fabrizio; Simone Di Franco; Francesco Dieli; Cinzia Garofalo; Klas Kärre; Rosanna La Rocca; Cristina Maccalli; Ofer Mandelboim; Alessandro Moretta; Camillo Palmieri; Pradeepa N Pangigadde; Giorgio Parmiani; Rosa Sottile; Giorgio Stassi; Ennio Carbone
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.
Journal of immunology (Baltimore, Md. : 1950) 2013;190(5):2381-90.
2012: Paola Filipazzi; Paola Frati; Felicetta Giardino; Claudia Lombardo; Michele Maio; Luigi Mariani; Andrea Maurichi; Giorgio Parmiani; Roberto Patuzzo; Lorenzo Pilla; Gianluigi Rigamonti; Marco Asioli; Chiara Camisaschi; Chiara Castelli; Vanna Chiarion-Sileni; Agata Cova; Riccardo Danielli; Annabella Di Florio; mario santinami; Gloria Sovena; Paola Squarcina; Gabrina Tragni; Antonello Villa; Licia Rivoltini
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(23):6485-96.
2012: Anna Maria Di Giacomo; Pier Francesco Ferrucci; Ester Fonsatti; Diana Giannarelli; Diego Annesi; Paolo A Ascierto; Antonella Marasco; Stefania Vl Nicoletti; Giorgio Parmiani; Lorenzo Pilla; Paola Queirolo; Ruggero Ridolfi; Licia Rivoltini; mario santinami; Ester Simeone; Alessandro Testori; Michele Maio
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
The lancet oncology 2012;13(9):879-86.
2012: Michele Maio; hugues nicolay; Michael Papamichail; Giulia Parisi; Giorgio Parmiani; Paola Queirolo; Ruggero Ridolfi; Vincenzo Russo; Paolo A Ascierto; Filippo Belardelli; Roberto Camerini; Mario P Colombo; Ester Fonsatti
Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer.
Cancer immunology, immunotherapy : CII 2012;61(9):1599-608.
2012: Tonia Mazzarella; Giulio Modorati; Elena Orsenigo; Giorgio Parmiani; Danilo Parolini; Lorenzo Pilla; Nathalie Rizzo; Valeria Cambiaghi; Annalisa Colucci; Claudio Doglioni; Cristina Maccalli
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
Cancer immunology, immunotherapy : CII 2012;61(8):1169-82.
2012: Chiara Bonini; Giorgio Parmiani
When transgenes shape immunity: cancer immune-gene therapy.
The journal of gene medicine 2012;14(6):384-5.
2012: Arianna Calcinotto; Rossella Canese; Agata Cova; Angelo De Milito; Stefano Fais; Paola Filipazzi; Luca Generoso; Matteo Grioni; Veronica Huber; Manuela Iero; Elena Jachetti; Giorgio Parmiani; Alessia Ricupito; Matteo Bellone; Martina Borghi; Monica Rossetti; mario santinami; Licia Rivoltini
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.
Cancer research 2012;72(11):2746-56.
2012: Arianna Calcinotto; Angelo Corti; Flavio Curnis; Matteo Grioni; Elena Jachetti; Anna Mondino; Giorgio Parmiani; Matteo Bellone
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2012;188(6):2687-94.
2011: Giorgio Parmiani; Lorenzo Pilla; Cristina Maccalli; Vincenzo Russo
Autologous versus allogeneic cell-based vaccines?
Cancer journal (Sudbury, Mass.) 2011;17(5):331-6.
2011: seyed amir jalali; Giorgio Parmiani
Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors.
Recent patents on biotechnology 2011;5(2):108-17.
2011: Michele Maio; hugues nicolay; Paolo A Ascierto; Filippo Belardelli; Roberto Camerini; Mario P Colombo; Paola Queirolo; Ruggero Ridolfi; Vincenzo Russo; Ester Fonsatti; Giorgio Parmiani
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.
Cancer immunology, immunotherapy : CII 2011;60(6):901-7.
2010: Michele Maio; hugues nicolay; Paolo A Ascierto; Filippo Belardelli; Roberto Camerini; Mario P Colombo; Paola Queirolo; Ruggero Ridolfi; Vincenzo Russo; Ester Fonsatti; Giorgio Parmiani
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009.
Cancer immunology, immunotherapy : CII 2010;59(12):1895-901.
2010: Michela Perego; Monica Tortoreto; Gabrina Tragni; Luigi Mariani; Paola Deho; Antonino Carbone; mario santinami; Roberto Patuzzo; Pamela Della Mina; Antonello Villa; Graziella Pratesi; Giacomo Cossa; Paola Perego; Maria G Daidone; Malcolm R Alison; Giorgio Parmiani; Licia Rivoltini; Chiara Castelli
Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells.
The Journal of investigative dermatology 2010;130(7):1877-86.
2010: Chiara Camisaschi; Chiara Casati; Francesca Rini; Michela Perego; Annamaria De Filippo; Frédéric Triebel; Giorgio Parmiani; Filiberto Belli; Licia Rivoltini; Chiara Castelli
LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(11):6545-51.
2010: Michele Maio; hugues nicolay; Paolo A Ascierto; Filippo Belardelli; Roberto Camerini; Mario P Colombo; Paola Queirolo; Ruggero Ridolfi; Vincenzo Russo; Ester Fonsatti; Giorgio Parmiani
Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008.
Cancer immunology, immunotherapy : CII 2010;59(6):963-9.
2010: Tiziano Di Tomaso; Stefania Mazzoleni; Ena Wang; Gloria Sovena; Daniela Clavenna; Alberto Franzin; pietro mortini; Soldano Ferrone; Claudio Doglioni; Francesco M Marincola; Rossella Galli; Giorgio Parmiani; Cristina Maccalli
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(3):800-13.
2009: Maria Daniotti; Andrea Ferrari; Simona Frigerio; Paola Casieri; Francesca Miselli; Elisa Zucca; Paola Collini; Gabriella Della Torre; Siranoush Manoukian; Bernard Peissel; Aldo Bono; mario santinami; Giorgio Parmiani; Licia Rivoltini; Silvana Pilotti; Monica Rodolfo
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
The Journal of investigative dermatology 2009;129(7):1759-68.
2009: Manuela Iero; Paola Filipazzi; Chiara Castelli; Filiberto Belli; Riccardo Valdagni; Giorgio Parmiani; Roberto Patuzzo; mario santinami; Licia Rivoltini
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
Cancer immunology, immunotherapy : CII 2009;58(7):1159-67.
2009: Cristina Maccalli; Samantha Scaramuzza; Giorgio Parmiani
TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Cancer immunology, immunotherapy : CII 2009;58(5):801-8.
2009: elena Tassi; Marco Braga; Renato Longhi; Francesca Gavazzi; Giorgio Parmiani; Valerio Di Carlo; Maria Pia Protti
Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients.
PloS one 2009;4(10):e7234.
2008: Cristina Maccalli; Veronica Di Cristanziano; Valentina Fodale; Domenico Corsi; Giuseppina D'Agostino; Valentina Petrangeli; Luca Laurenti; Sofia Guida; Arabella Mazzocchi; Flavio Arienti; Maria P Perrone; Chiara Castelli; Licia Rivoltini; Vittorina Zagonel; Marco Tartaglia; Giorgio Parmiani; Filippo Belardelli
Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7292-303.
2008: AnnaMaria De Filippo; Robert J Binder; Chiara Camisaschi; Valeria Beretta; Flavio Arienti; Antonello Villa; Pamela Della Mina; Giorgio Parmiani; Licia Rivoltini; Chiara Castelli
Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(9):6525-35.
2008: Luca Vezzoni; Giorgio Parmiani
Limitations of the cancer stem cell theory.
Cytotechnology 2008;58(1):3-9.
2008: Luisa Novellino; Annamaria De Filippo; Paola Deho; Federica Perrone; Silvana Pilotti; Giorgio Parmiani; Chiara Castelli
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.
Cellular signalling 2008;20(5):872-83.
2008: Chiara Casati; Chiara Camisaschi; Luisa Novellino; Arabella Mazzocchi; Frédéric Triebel; Licia Rivoltini; Giorgio Parmiani; Chiara Castelli
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(6):3782-8.
2008: Michele Maio; Ester Fonsatti; Arianna Burigo; Giorgio Parmiani
The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level.
Tumori 2008;94(2):179-81.
2008: Viviana Vallacchi; Maria Daniotti; Francesca Ratti; Delia Di Stasi; Paola Deho; Annamaria De Filippo; Gabrina Tragni; Andrea Balsari; Antonino Carbone; Licia Rivoltini; Giorgio Parmiani; Noureddine Lazar; Bernard Perbal; Monica Rodolfo
CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.
Cancer research 2008;68(3):715-23.
2008: Michele Maio; hugues nicolay; Paolo Ascierto; Filippo Belardelli; Roberto Camerini; Mario P Colombo; Paola Queirolo; Ruggero Ridolfi; Vincenzo Russo; Lucia Anzalone; Ester Fonsatti; Giorgio Parmiani
The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.
Journal of translational medicine 2008;6():8.
2008: Manuela Iero; Roberta Valenti; Veronica Huber; Paola Filipazzi; Giorgio Parmiani; Stefano Fais; Licia Rivoltini
Tumour-released exosomes and their implications in cancer immunity.
Cell death and differentiation 2008;15(1):80-8.
2007: Cristina Maccalli; Daisuke Nonaka; Adriano Piris; Daniela Pende; Licia Rivoltini; Chiara Castelli; Giorgio Parmiani
NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7459-68.
2007: Manuela Iero; Paola Squarcina; Pedro Romero; Philippe Guillaume; Elisa Scarselli; Raffaele Cerino; Matteo Carrabba; Olivier Toutirais; Giorgio Parmiani; Licia Rivoltini
Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.
Cancer immunology, immunotherapy : CII 2007;56(12):1979-91.
2007: Giorgio Parmiani; Vincenzo Russo; Andrea Marrari; Gianluca Cutolo; Chiara Casati; Lorenzo Pilla; Cristina Maccalli; Licia Rivoltini; Chiara Castelli
Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5675-9.
2007: Michele Del Vecchio; Emilio Bajetta; Stefania Canova; Michael T Lotze; Amy Wesa; Giorgio Parmiani; Andrea Anichini
Interleukin-12: biological properties and clinical application.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4677-85.
2007: Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(18):2546-53.
2007: Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Phenotypic characterization of human colorectal cancer stem cells.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(24):10158-63.
2007: Maria Daniotti; Viviana Vallacchi; Licia Rivoltini; Roberto Patuzzo; mario santinami; Flavio Arienti; Gianluca Cutolo; Marco A Pierotti; Giorgio Parmiani; Monica Rodolfo
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.
International journal of cancer. Journal international du cancer 2007;120(11):2439-44.
2007: Roberta Valenti; Veronica Huber; Manuela Iero; Paola Filipazzi; Giorgio Parmiani; Licia Rivoltini
Tumor-released microvesicles as vehicles of immunosuppression.
Cancer research 2007;67(7):2912-5.
2007: Maria Ferrantini; Imerio Capone; Francesco M Marincola; Giorgio Parmiani; Filippo Belardelli
International meeting "Immunotherapy of cancer: challenges and needs".
Cancer immunology, immunotherapy : CII 2007;56(4):581-5.
2007: Andrea Marrari; Manuela Iero; Lorenzo Pilla; Sergio Villa; Roberto Salvioni; Riccardo Valdagni; Giorgio Parmiani; Licia Rivoltini
Vaccination therapy in prostate cancer.
Cancer immunology, immunotherapy : CII 2007;56(4):429-45.
2007: Giorgio Parmiani; Chiara Castelli; mario santinami; Licia Rivoltini
Melanoma immunology: past, present and future.
Current opinion in oncology 2007;19(2):121-7.
2007: Giorgio Parmiani; Annamaria De Filippo; Luisa Novellino; Chiara Castelli
Unique human tumor antigens: immunobiology and use in clinical trials.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(4):1975-9.
2007: Giorgio Parmiani; Chiara Castelli; Lorenzo Pilla; mario santinami; M P Colombo; Licia Rivoltini
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):226-32.
2006: Roberta Valenti; Veronica Huber; Paola Filipazzi; Lorenzo Pilla; Gloria Sovena; Antonello Villa; Alessandro Corbelli; Stefano Fais; Giorgio Parmiani; Licia Rivoltini
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Cancer research 2006;66(18):9290-8.
2006: Lorenzo Pilla; Roberta Valenti; Andrea Marrari; Roberto Patuzzo; mario santinami; Giorgio Parmiani; Licia Rivoltini
Vaccination: role in metastatic melanoma.
Expert review of anticancer therapy 2006;6(8):1305-18.
2006: Lorenzo Pilla; Roberto Patuzzo; Licia Rivoltini; Michele Maio; Elisabetta Pennacchioli; Elda Lamaj; Andrea Maurichi; Samuele Massarut; Alfonso Marchianò; Cristina Santantonio; Diego Tosi; Flavio Arienti; Agata Cova; Gloria Sovena; Adriano Piris; Daisuke Nonaka; Ilaria Bersani; Annabella Di Florio; Mariani Luigi; Pramod K Srivastava; Axel Hoos; mario santinami; Giorgio Parmiani
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Cancer immunology, immunotherapy : CII 2006;55(8):958-68.
2006: Marialuisa Sensi; Gabriella Nicolini; C Petti; Ilaria Bersani; Francesco Lozupone; Alessandra Molla; Claudia Vegetti; Daisuke Nonaka; Roberta Mortarini; Giorgio Parmiani; Stefano Fais; Andrea Anichini
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.
Oncogene 2006;25(24):3357-64.
2006: Giorgio Parmiani; Annamaria De Filippo; Lorenzo Pilla; Chiara Castelli; Licia Rivoltini
Heat shock proteins gp96 as immunogens in cancer patients.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(3):223-7.
2006: Tiziana Di Pucchio; Lorenzo Pilla; Imerio Capone; Maria Ferrantini; Enrica Montefiore; Francesca Urbani; Roberto Patuzzo; Elisabetta Pennacchioli; mario santinami; Agata Cova; Gloria Sovena; Flavio Arienti; Claudia Lombardo; Arianna Lombardi; Patrizia Caporaso; Stefania D'Atri; Piero Marchetti; Enzo Bonmassar; Giorgio Parmiani; Filippo Belardelli; Licia Rivoltini
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Cancer research 2006;66(9):4943-51.
2006: Chiara Casati; Chiara Camisaschi; Francesca Rini; Flavio Arienti; Licia Rivoltini; Frédéric Triebel; Giorgio Parmiani; Chiara Castelli
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.
Cancer research 2006;66(8):4450-60.
2006: Luana Lugini; Paola Matarrese; Antonella Tinari; Francesco Lozupone; Cristina Federici; Elisabetta Iessi; Massimo Gentile; Francesca Luciani; Giorgio Parmiani; Licia Rivoltini; Walter Malorni; Stefano Fais
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells.
Cancer research 2006;66(7):3629-38.
2005: Giorgio Parmiani
Tumor-infiltrating T cells--friend or foe of neoplastic cells?
The New England journal of medicine 2005;353(25):2640-1.
2005: Monica Rodolfo; Marco A Pierotti; Giorgio Parmiani
A merging duo in melanoma formation.
The Journal of investigative dermatology 2005;125(6):xii-xiii.
2005: Veronica Huber; Stefano Fais; Manuela Iero; Luana Lugini; Paola Canese; Paola Squarcina; Annamaria Zaccheddu; Marisa Colone; Giuseppe Arancia; Massimo Gentile; Ettore Seregni; Roberta Valenti; Giuseppina Ballabio; Filiberto Belli; Ermanno Leo; Giorgio Parmiani; Licia Rivoltini
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.
Gastroenterology 2005;128(7):1796-804.
2005: Lorenzo Pilla; Paola Squarcina; Jorgelina Coppa; Vincenzo Mazzaferro; Veronica Huber; Daniela Pende; Cristina Maccalli; Gloria Sovena; Luigi Mariani; Chiara Castelli; Giorgio Parmiani; Licia Rivoltini
Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
Cancer research 2005;65(9):3942-9.
2005: Licia Rivoltini; Paola Canese; Veronica Huber; Manuela Iero; Lorenzo Pilla; Roberta Valenti; Stefano Fais; Francesco Lozupone; Chiara Casati; Chiara Castelli; Giorgio Parmiani
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
Expert opinion on biological therapy 2005;5(4):463-76.
2005: Piero Dalerba; Cristiana Guiducci; Pietro Luigi Poliani; Ingrid Cifola; Mariella Parenza; Milo Frattini; Gianfrancesco Gallino; Ileana Carnevali; Ilvia Di Giulio; Salvatore Andreola; Claudia Lombardo; Licia Rivoltini; Tamás Schweighoffer; Filiberto Belli; Mario P Colombo; Giorgio Parmiani; Chiara Castelli
Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells.
Cancer research 2005;65(6):2321-9.
2005: Luisa Novellino; Chiara Castelli; Giorgio Parmiani
A listing of human tumor antigens recognized by T cells: March 2004 update.
Cancer immunology, immunotherapy : CII 2005;54(3):187-207.
2005: Marialuisa Sensi; Gabriella Nicolini; Marina Zanon; Chiara Colombo; Alessandra Molla; Ilaria Bersani; Raffaella Lupetti; Giorgio Parmiani; Andrea Anichini
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
Cancer research 2005;65(2):632-40.
2004: Giorgio Parmiani; Alessandro Testori; Michele Maio; Chiara Castelli; Licia Rivoltini; Lorenzo Pilla; Filiberto Belli; Vincenzo Mazzaferro; Jorgelina Coppa; Roberto Patuzzo; Mario Roberto Sertoli; Axel Hoos; Pramod K Srivastava; mario santinami
Heat shock proteins and their use as anticancer vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8142-6.
2004: Francesca Luciani; Massimo Spada; Angelo De Milito; Agnese Molinari; Licia Rivoltini; Annalisa Montinaro; Manuela Marra; Luana Lugini; Mariantonia Logozzi; Francesco Lozupone; Cristina Federici; Elisabetta Iessi; Giorgio Parmiani; Giuseppe Arancia; Filippo Belardelli; Stefano Fais
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Journal of the National Cancer Institute 2004;96(22):1702-13.
2004: Filippo Belardelli; Maria Ferrantini; Giorgio Parmiani; Jeffrey Schlom; Enrico Garaci
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
Cancer research 2004;64(18):6827-30.
2004: Massimo Di Nicola; Carmelo Carlo-Stella; Roberta Mortarini; Paola Baldassari; Anna Guidetti; Gianfrancesco Gallino; Michele Del Vecchio; Fernando Ravagnani; Michele Magni; Paul Chaplin; Natale Cascinelli; Giorgio Parmiani; ALESSANDRO MASSIMO GIANNI; Andrea Anichini
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5381-90.
2004: Maria Daniotti; Maria Oggionni; Tiziana Ranzani; Viviana Vallacchi; Valentina Campi; Delia Di Stasi; Gabriella Della Torre; Federica Perrone; Chiara Luoni; Simona Suardi; Milo Frattini; Silvana Pilotti; Andrea Anichini; Gabrina Tragni; Giorgio Parmiani; Marco A Pierotti; Monica Rodolfo
BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Oncogene 2004;23(35):5968-77.
2004: Diego Tosi; Roberta Valenti; Agata Cova; Gloria Sovena; Veronica Huber; Lorenzo Pilla; Flavio Arienti; Filippo Belardelli; Giorgio Parmiani; Licia Rivoltini
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(9):5363-70.
2004: Chiara Castelli; Licia Rivoltini; Francesca Rini; Filiberto Belli; Alessandro Testori; Michele Maio; Vincenzo Mazzaferro; Jorgelina Coppa; Pramod K Srivastava; Giorgio Parmiani
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer.
Cancer immunology, immunotherapy : CII 2004;53(3):227-33.
2004: Francesco Lozupone; Daniela Pende; Vito Lelio Burgio; Chiara Castelli; Massimo Spada; Massimo Venditti; Francesca Luciani; Luana Lugini; Cristina Federici; Carlo Ramoni; Licia Rivoltini; Giorgio Parmiani; Filippo Belardelli; Paola Rivera; Stefania Marcenaro; Lorenzo Moretta; Stefano Fais
Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.
Cancer research 2004;64(1):378-85.
2003: Giorgio Parmiani; Chiara Castelli; Licia Rivoltini; Chiara Casati; Glenn A Tully; Luisa Novellino; Andrea Patuzzo; Diego Tosi; Andrea Anichini; mario santinami
Immunotherapy of melanoma.
Seminars in cancer biology 2003;13(6):391-400.
2003: Luana Lugini; Francesco Lozupone; Paola Matarrese; Cristina Funaro; Francesca Luciani; Walter Malorni; Licia Rivoltini; Chiara Castelli; Antonella Tinari; Adriano Piris; Giorgio Parmiani; Stefano Fais
Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin.
Laboratory investigation; a journal of technical methods and pathology 2003;83(11):1555-67.
2003: Monica Rodolfo; Roberto Luksch; Elisabeth Stockert; Yao-Tseng Chen; Paola Collini; Tiziana Ranzani; Claudia Lombardo; Piero Dalerba; Licia Rivoltini; Flavio Arienti; Franca Fossati-Bellani; Lloyd J Old; Giorgio Parmiani; Chiara Castelli
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Cancer research 2003;63(20):6948-55.
2003: Licia Rivoltini; Chiara Castelli; Matteo Carrabba; Vincenzo Mazzaferro; Lorenzo Pilla; Veronica Huber; Jorgelina Coppa; Gianfrancesco Gallino; Carmen Scheibenbogen; Paola Squarcina; Agata Cova; Roberto Camerini; Jonathan J Lewis; Pramod K Srivastava; Giorgio Parmiani
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(7):3467-74.
2003: Massimo Di Nicola; Carmelo Carlo-Stella; Andrea Anichini; Roberta Mortarini; Anna Guidetti; Gabrina Tragni; Francesco Gallino; Michele Del Vecchio; Fernando Ravagnani; Daniele Morelli; Paul Chaplin; Nathaly Arndtz; Gerd Sutter; Ingo Drexler; Giorgio Parmiani; Natale Cascinelli; ALESSANDRO MASSIMO GIANNI
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
Human gene therapy 2003;14(14):1347-60.
2003: Vincenzo Mazzaferro; Jorgelina Coppa; Matteo Carrabba; Licia Rivoltini; Marcello Schiavo; Enrico Regalia; Luigi Mariani; Tiziana Camerini; Alfonso Marchianò; Salvatore Andreola; Roberto Camerini; Marco Corsi; Jonathan J Lewis; Pramod K Srivastava; Giorgio Parmiani
Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3235-45.
2003: Chiara Casati; Piero Dalerba; Licia Rivoltini; Gianfrancesco Gallino; Paola Deho; Francesca Rini; Filiberto Belli; Delia Mezzanzanica; Aurora Costa; Salvatore Andreola; Ermanno Leo; Giorgio Parmiani; Chiara Castelli
The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
Cancer research 2003;63(15):4507-15.
2003: Cristina Maccalli; Daniela Pende; Chiara Castelli; Maria Cristina Mingari; Paul F Robbins; Giorgio Parmiani
NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
European journal of immunology 2003;33(7):2033-43.
2003: Luisa Novellino; Nicolina Renkvist; Francesca Rini; Arabella Mazzocchi; Licia Rivoltini; Angela Greco; Paola Deho; Paola Squarcina; Paul F Robbins; Giorgio Parmiani; Chiara Castelli
Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(12):6363-70.
2003: Giorgio Parmiani; Lorenzo Pilla; Chiara Castelli; Licia Rivoltini
Vaccination of patients with solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):817-24.
2003: Roberta Mortarini; Adriano Piris; Andrea Maurichi; Alessandra Molla; Ilaria Bersani; Aldo Bono; Cesare Bartoli; mario santinami; Claudia Lombardo; Fernando Ravagnani; Natale Cascinelli; Giorgio Parmiani; Andrea Anichini
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Cancer research 2003;63(10):2535-45.
2003: Piero Dalerba; Cristina Maccalli; Chiara Casati; Chiara Castelli; Giorgio Parmiani
Immunology and immunotherapy of colorectal cancer.
Critical reviews in oncology/hematology 2003;46(1):33-57.
2003: Matteo Carrabba; Chiara Castelli; Markus J Maeurer; Paola Squarcina; Agata Cova; Lorenzo Pilla; Nicolina Renkvist; Giorgio Parmiani; Licia Rivoltini
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Cancer research 2003;63(7):1560-7.
2003: Francesco Lozupone; Licia Rivoltini; Francesca Luciani; Massimo Venditti; Luana Lugini; Agata Cova; Paola Squarcina; Giorgio Parmiani; Filippo Belardelli; Stefano Fais
Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
European journal of immunology 2003;33(2):556-66.
2002: Filiberto Belli; Alessandro Testori; Licia Rivoltini; Michele Maio; Giovanna Andreola; Mario Roberto Sertoli; Gianfrancesco Gallino; Adriano Piris; Alessandro Cattelan; Ivano Lazzari; Matteo Carrabba; Giorgio Scita; Cristina Santantonio; Lorenzo Pilla; Gabrina Tragni; Claudia Lombardo; Flavio Arienti; Alfonso Marchianò; Paola Queirolo; Francesco Bertolini; Agata Cova; Elda Lamaj; Lucio Ascani; Roberto Camerini; Marco Corsi; Natale Cascinelli; Jonathan J Lewis; Pramod Srivastava; Giorgio Parmiani
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(20):4169-80.
2002: Licia Rivoltini; Matteo Carrabba; Veronica Huber; Chiara Castelli; Luisa Novellino; Piero Dalerba; Roberta Mortarini; Giuseppe Arancia; Andrea Anichini; Stefano Fais; Giorgio Parmiani
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
Immunological reviews 2002;188():97-113.
2002: Giorgio Parmiani; Marialuisa Sensi; Chiara Castelli; Licia Rivoltini; Andrea Anichini
T-cell response to unique and shared antigens and vaccination of cancer patients.
Cancer immunity 2002;2():6.
2002: Giorgio Parmiani; Chiara Castelli; Piero Dalerba; Roberta Mortarini; Licia Rivoltini; Francesco M Marincola; Andrea Anichini
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Journal of the National Cancer Institute 2002;94(11):805-18.
2002: Giovanna Andreola; Licia Rivoltini; Chiara Castelli; Veronica Huber; Paola Perego; Paola Deho; Paola Squarcina; Paola Accornero; Francesco Lozupone; Luana Lugini; Annarita Stringaro; Agnese Molinari; Giuseppe Arancia; Massimo Gentile; Giorgio Parmiani; Stefano Fais
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.
The Journal of experimental medicine 2002;195(10):1303-16.
2002: Marialuisa Sensi; S Pellegatta; Claudia Vegetti; Gabriella Nicolini; Giorgio Parmiani; Andrea Anichini
Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.
Tissue antigens 2002;59(4):273-9.
2002: Paola Matarrese; Luigi Di Biase; Laura Santodonato; Elisabetta Straface; Monica Mecchia; Barbara Ascione; Giorgio Parmiani; Filippo Belardelli; Maria Ferrantini; Walter Malorni
Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function.
The American journal of pathology 2002;160(4):1507-20.
2002: Marilisa Carsana; Gabrina Tragni; Gabriella Nicolini; Ilaria Bersani; Giorgio Parmiani; Andrea Anichini; Yuan Sheng Sun; Peter Möller; Dirk Schadendorf; Marialuisa Sensi
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine.
Cancer gene therapy 2002;9(3):243-53.
2002: Michele Maio; Ester Fonsatti; Elda Lamaj; Maresa Altomonte; Ilaria Cattarossi; Cristina Santantonio; Cecilia Melani; Filiberto Belli; Flavio Arienti; Mario P Colombo; Giorgio Parmiani
Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.
Cancer immunology, immunotherapy : CII 2002;51(1):9-14.
2001: Gabriella Della Torre; Barbara Pasini; S Frigerio; R Donghi; D Rovini; Domenico Delia; G Peters; T J Huot; Giovanna Bianchi-Scarra; Francesca Lantieri; Monica Rodolfo; Giorgio Parmiani; Marco A Pierotti
CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
British journal of cancer 2001;85(6):836-44.
2001: Monica Rodolfo; Enrica Mira Catò; Sabina Soldati; Roberta Ceruti; M Asioli; Eugenio Scanziani; Paolo Vezzoni; Giorgio Parmiani; Maria Grazia Sacco
Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy.
Cancer gene therapy 2001;8(7):491-6.
2001: Arabella Mazzocchi; Cecilia Melani; Licia Rivoltini; Chiara Castelli; M Del Vecchio; Claudia Lombardo; Mario P Colombo; Giorgio Parmiani
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes.
Cancer immunology, immunotherapy : CII 2001;50(4):199-211.
2001: Nicolina Renkvist; Chiara Castelli; Paul F Robbins; Giorgio Parmiani
A listing of human tumor antigens recognized by T cells.
Cancer immunology, immunotherapy : CII 2001;50(1):3-15.
2001: Giorgio Parmiani; Chiara Castelli; Piero Dalerba; Licia Rivoltini
T cell response to tumor antigens and its therapeutic use in cancer patients.
Advances in experimental medicine and biology 2001;495():403-10.
2001: Chiara Castelli; Anne-Marie T Ciupitu; Francesca Rini; Licia Rivoltini; Arabella Mazzocchi; Rolf Kiessling; Giorgio Parmiani
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.
Cancer research 2001;61(1):222-7.
2000: A J Bremers; Salvatore Andreola; Ermanno Leo; Francesco Gallino; Francesca Rini; Claudia Lombardo; Filiberto Belli; Peter Kuppen; Giorgio Parmiani; Chiara Castelli
T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens.
International journal of cancer. Journal international du cancer 2000;88(6):956-61.
2000: Giorgio Parmiani; Licia Rivoltini; Giovanna Andreola; Matteo Carrabba
Cytokines in cancer therapy.
Immunology letters 2000;74(1):41-4.
2000: Francesco Lozupone; Francesca Luciani; Massimo Venditti; Licia Rivoltini; S Pupa; Giorgio Parmiani; Filippo Belardelli; Stefano Fais
Murine granulocytes control human tumor growth in SCID mice.
International journal of cancer. Journal international du cancer 2000;87(4):569-73.
2000: P Pisarra; Raffaella Lupetti; Anna Palumbo; Alessandra Napolitano; Giuseppe Prota; Giorgio Parmiani; Andrea Anichini; Marialuisa Sensi
Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization.
The Journal of investigative dermatology 2000;115(1):48-56.
2000: Giorgio Parmiani; Monica Rodolfo; Cecilia Melani
Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal.
Human gene therapy 2000;11(9):1269-75.
2000: A J Bremers; Giorgio Parmiani
Immunology and immunotherapy of human cancer: present concepts and clinical developments.
Critical reviews in oncology/hematology 2000;34(1):1-25.
2000: Chiara Castelli; Licia Rivoltini; Giovanna Andreola; Matteo Carrabba; Nicolina Renkvist; Giorgio Parmiani
T-cell recognition of melanoma-associated antigens.
Journal of cellular physiology 2000;182(3):323-31.
2000: Giorgio Parmiani
Immunological therapy of human tumors by gene-modified cellular vaccines.
Folia biologica 2000;46(6):207-9.
2000: Monica Mecchia; Paola Matarrese; Walter Malorni; Giuseppina D'Agostino; Paola Sestili; Stefano M Santini; Maria Cristina Gauzzi; Massimo Venditti; A Mazzocchi; Giorgio Parmiani; Filippo Belardelli; Maria Ferrantini
Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha.
Gene therapy 2000;7(2):167-79.
1999: C Maccalli; P Pisarra; Claudia Vegetti; Marialuisa Sensi; Giorgio Parmiani; Andrea Anichini
Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(12):6912-23.
1999: Flavio Arienti; Filiberto Belli; F Napolitano; J Sulé-Suso; Arabella Mazzocchi; Gianfrancesco Gallino; Alessandro Cattelan; Cristina Santantonio; Licia Rivoltini; Cecilia Melani; Mario P Colombo; Natale Cascinelli; Michele Maio; Giorgio Parmiani; C Sanantonio
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells.
Human gene therapy 1999;10(18):2907-16.
1999: M Castellano; Giorgio Parmiani
Genes involved in melanoma: an overview of INK4a and other loci.
Melanoma research 1999;9(5):421-32.
1999: Andrea Anichini; Alessandra Molla; Roberta Mortarini; Gabrina Tragni; Ilaria Bersani; Massimo Di Nicola; ALESSANDRO MASSIMO GIANNI; Silvana Pilotti; R Dunbar; V Cerundolo; Giorgio Parmiani
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
The Journal of experimental medicine 1999;190(5):651-67.
1999: Monica Rodolfo; C Zilocchi; B Cappetti; Giorgio Parmiani; Cecilia Melani; Mario P Colombo
Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine.
Gene therapy 1999;6(5):865-72.
1999: P Pisarra; Roberta Mortarini; S Salvi; Andrea Anichini; Giorgio Parmiani; Marialuisa Sensi
High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition.
Cancer immunology, immunotherapy : CII 1999;48(1):39-46.
1999: Chiara Castelli; P Tarsini; Arabella Mazzocchi; Francesca Rini; Licia Rivoltini; Fernando Ravagnani; Francesco Gallino; Filiberto Belli; Giorgio Parmiani
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1739-48.
1999: Licia Rivoltini; Paola Squarcina; DJ Loftus; Chiara Castelli; P Tarsini; Arabella Mazzocchi; Francesca Rini; V Viggiano; Filiberto Belli; Giorgio Parmiani
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.
Cancer research 1999;59(2):301-6.
1998: Massimo Di Nicola; Salvatore Siena; Marco Bregni; Paolo Longoni; Michele Magni; Marco Milanesi; Paola Matteucci; Roberta Mortarini; Andrea Anichini; Giorgio Parmiani; Ingo Drexler; Volker Erfle; Gerd Sutter; ALESSANDRO MASSIMO GIANNI
Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.
Cancer gene therapy 1998;5(6):350-6.
1998: Raffaella Lupetti; P Pisarra; A Verrecchia; C Farina; Gabriella Nicolini; Andrea Anichini; Claudio Bordignon; Marialuisa Sensi; Giorgio Parmiani; Catia Traversari
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.
The Journal of experimental medicine 1998;188(6):1005-16.
1998: Cecilia Melani; Mariangela Figini; D Nicosia; Elena Luison; V Ramakrishna; G Casorati; Giorgio Parmiani; Zelig Eshhar; Silvana Canevari; Mario P Colombo
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Cancer research 1998;58(18):4146-54.
1998: Z Wang; Flavio Arienti; Giorgio Parmiani; Soldano Ferrone
Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells.
European journal of immunology 1998;28(9):2817-26.
1998: Licia Rivoltini; Marina Radrizzani; Paola Accornero; Paola Squarcina; Claudia Chiodoni; Arabella Mazzocchi; Chiara Castelli; P Tarsini; V Viggiano; Filiberto Belli; Mario P Colombo; Giorgio Parmiani
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(3):1220-30.
1998: Giorgio Parmiani
Future perspectives in specific immunotherapy of melanoma.
European journal of cancer (Oxford, England : 1990) 1998;34 Suppl 3():S42-7.
1998: DJ Hicklin; Z Wang; Flavio Arienti; Licia Rivoltini; Giorgio Parmiani; Soldano Ferrone
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
The Journal of clinical investigation 1998;101(12):2720-9.
1998: DJ Loftus; Paola Squarcina; M B Nielsen; Carsten Geisler; Chiara Castelli; Niels Odum; Ettore Appella; Giorgio Parmiani; Licia Rivoltini
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
Cancer research 1998;58(11):2433-9.
1998: Marialuisa Sensi; C Farina; C Maccalli; Andrea Anichini; D Berd; Giorgio Parmiani
Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(3):198-204.
1998: Claudio Clemente; S Rao; Raffaella Lupetti; Gabrina Tragni; P Pisarra; Ilaria Bersani; Giorgio Parmiani; M C Mihm; Marialuisa Sensi
Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma.
Laboratory investigation; a journal of technical methods and pathology 1998;78(5):619-27.
1998: Chiara Castelli; Arabella Mazzocchi; Francesca Rini; P Tarsini; Licia Rivoltini; Michele Maio; Gianfrancesco Gallino; Filiberto Belli; Giorgio Parmiani
Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
European journal of immunology 1998;28(4):1143-54.
1998: F Belli; Luigi Mascheroni; Gianfrancesco Gallino; Leonardo Lenisa; Flavio Arienti; Cecilia Melani; M P Colombo; Giorgio Parmiani; N Cascinelli
Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells.
Advances in experimental medicine and biology 1998;451():543-5.
1998: Emilio Bajetta; Michele Del Vecchio; Roberta Mortarini; R Nadeau; Ashok Rakhit; Lorenza Rimassa; C Fowst; A Borri; Andrea Anichini; Giorgio Parmiani
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):75-85.
1998: Licia Rivoltini; DJ Loftus; Paola Squarcina; Chiara Castelli; Francesca Rini; Flavio Arienti; Filiberto Belli; F M Marincola; Carsten Geisler; A Borsatti; Ettore Appella; Giorgio Parmiani
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.
Critical reviews in immunology 1998;18(1-2):55-63.
1997: V Ramakrishna; DR Negri; V Brusic; R Fontanelli; Silvana Canevari; G Bolis; Chiara Castelli; Giorgio Parmiani
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells.
International journal of cancer. Journal international du cancer 1997;73(1):143-50.
1997: Carla Bertazzoli; Edoardo Marchesi; Said Dermime; Fernando Ravagnani; Giorgio Parmiani; Carlo Gambacorti-Passerini
HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins.
Tumori 1997;83(5):847-55.
1997: Giorgio Parmiani; Andrea Anichini; Chiara Castelli
New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses.
Melanoma research 1997;7 Suppl 2():S95-8.
1997: C Maccalli; C Farina; Marialuisa Sensi; Giorgio Parmiani; Andrea Anichini
TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(12):5902-13.
1997: Filiberto Belli; Flavio Arienti; J Sulé-Suso; Claudio Clemente; Luigi Mascheroni; Alessandro Cattelan; Cristina Santantonio; Gianfrancesco Gallino; Cecilia Melani; S Rao; Mario P Colombo; Michele Maio; Natale Cascinelli; Giorgio Parmiani; C Sanatonio
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability.
Cancer immunology, immunotherapy : CII 1997;44(4):197-203.
1997: Carlo Gambacorti-Passerini; Carla Bertazzoli; Said Dermime; Antonio Scardino; D Schendel; Giorgio Parmiani
Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):675-83.
1997: Marialuisa Sensi; C Farina; C Maccalli; Raffaella Lupetti; Gabriella Nicolini; Andrea Anichini; Giorgio Parmiani; D Berd
Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.
The Journal of clinical investigation 1997;99(4):710-7.
1997: Chiara Castelli; Licia Rivoltini; Arabella Mazzocchi; Giorgio Parmiani
T-cell recognition of melanoma antigens and its therapeutic applications.
International journal of clinical & laboratory research 1997;27(2):103-10.
1997: Giorgio Parmiani; Mario P Colombo; Cecilia Melani; Flavio Arienti
Cytokine gene transduction in the immunotherapy of cancer.
Advances in pharmacology (San Diego, Calif.) 1997;40():259-307.
1996: Flavio Arienti; J Sulé-Suso; Filiberto Belli; Luigi Mascheroni; Licia Rivoltini; Cecilia Melani; Michele Maio; Natale Cascinelli; Mario P Colombo; Giorgio Parmiani
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.
Human gene therapy 1996;7(16):1955-63.
1996: Arabella Mazzocchi; Walter J Storkus; Catia Traversari; P Tarsini; Markus J Maeurer; Licia Rivoltini; C Vegetti; Filiberto Belli; Andrea Anichini; Giorgio Parmiani; Chiara Castelli
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(7):3030-8.
1996: M A Player; K C Barracchini; TB Simonis; Licia Rivoltini; Flavio Arienti; Chiara Castelli; Arabella Mazzocchi; Filiberto Belli; Giorgio Parmiani; Francesco M Marincola
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(5):357-63.
1996: C Farina; Pierre van der Bruggen; P Boël; Giorgio Parmiani; Marialuisa Sensi
Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens.
International immunology 1996;8(9):1463-6.
1996: A Caré; A Silvani; ettore meccia; Gianfranco Mattia; A Stoppacciaro; Giorgio Parmiani; Cesare Peschle; Mario P Colombo
HOXB7 constitutively activates basic fibroblast growth factor in melanomas.
Molecular and cellular biology 1996;16(9):4842-51.
1996: DJ Loftus; Chiara Castelli; Timothy M Clay; Paola Squarcina; Francesco M Marincola; Michael I Nishimura; Giorgio Parmiani; Ettore Appella; Licia Rivoltini
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
The Journal of experimental medicine 1996;184(2):647-57.
1996: Licia Rivoltini; DJ Loftus; K Barracchini; Flavio Arienti; Arabella Mazzocchi; W E Biddison; Michael L Salgaller; Ettore Appella; Giorgio Parmiani; Francesco M Marincola
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(10):3882-91.
1996: Said Dermime; Carla Bertazzoli; Edoardo Marchesi; Fernando Ravagnani; K Blaser; Gianmarco Corneo; Enrico Pogliani; Giorgio Parmiani; Carlo Gambacorti-Passerini
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):593-600.
1996: M Vagliani; Monica Rodolfo; Federica Cavallo; Mariella Parenza; Cecilia Melani; Giorgio Parmiani; G Forni; Mario P Colombo
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells.
Cancer research 1996;56(3):467-70.
1996: Giorgio Parmiani; Flavio Arienti; J Sulé-Suso; Cecilia Melani; Mario P Colombo; V Ramakrishna; Filiberto Belli; Luigi Mascheroni; Licia Rivoltini; Natale Cascinelli
Cytokine-based gene therapy of human tumors. An overview.
Folia biologica 1996;42(6):305-9.
1996: Andrea Anichini; Roberta Mortarini; C Maccalli; Paola Squarcina; K Fleischhauer; Luigi Mascheroni; Giorgio Parmiani
Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):208-17.
1995: M Sensi; Giorgio Parmiani
Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses.
Immunology today 1995;16(12):588-95.
1995: Cecilia Melani; J Sulé-Suso; Flavio Arienti; C Maccalli; F Passerini; Mario P Colombo; Giorgio Parmiani
A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype.
Human gene therapy 1995;6(11):1427-36.
1995: Giorgio Parmiani; Mario P Colombo
Somatic gene therapy of human melanoma: preclinical studies and early clinical trials.
Melanoma research 1995;5(5):295-301.
1995: J Sulé-Suso; Flavio Arienti; Cecilia Melani; Mario P Colombo; Giorgio Parmiani
A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes.
European journal of immunology 1995;25(10):2737-42.
1995: Cecilia Melani; S M Pupa; Antonella Stoppacciaro; S Ménard; M I Colnaghi; Giorgio Parmiani; Mario P Colombo
An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines.
International journal of cancer. Journal international du cancer 1995;62(5):572-8.
1995: S Salvi; F Segalla; S Rao; Flavio Arienti; M Sartori; G Bratina; E Caronni; Andrea Anichini; Claudio Clemente; Giorgio Parmiani
Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas.
Cancer research 1995;55(15):3374-9.
1995: A Silvani; G Ferrari; Giacomo Paonessa; Carlo Toniatti; Giorgio Parmiani; Mario P Colombo
Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.
Cancer research 1995;55(10):2200-5.
1995: A Martinotti; Antonella Stoppacciaro; M Vagliani; Cecilia Melani; F Spreafico; M Wysocka; Giorgio Parmiani; G Trinchieri; Mario P Colombo
CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
European journal of immunology 1995;25(1):137-46.
1995: Chiara Castelli; Walter J Storkus; Markus J Maeurer; D M Martin; E C Huang; B N Pramanik; TL Nagabhushan; Giorgio Parmiani; Michael T Lotze
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.
The Journal of experimental medicine 1995;181(1):363-8.
1994: Chiara Castelli; Marialuisa Sensi; Raffaella Lupetti; Roberta Mortarini; P Panceri; Andrea Anichini; Giorgio Parmiani
Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene.
Cancer research 1994;54(17):4785-90.
1994: Amerigo Boiardi; Antonio Silvani; P A Ruffini; Licia Rivoltini; Giorgio Parmiani; Giovanni Broggi; Andrea Salmaggi
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
Cancer immunology, immunotherapy : CII 1994;39(3):193-7.
1994: Flavio Arienti; J Sulé-Suso; Cecilia Melani; C Maccalli; Filiberto Belli; M T Illeni; Andrea Anichini; Natale Cascinelli; Mario P Colombo; Giorgio Parmiani
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.
Human gene therapy 1994;5(9):1139-50.
1994: Arabella Mazzocchi; Filiberto Belli; Luigi Mascheroni; C Vegetti; Giorgio Parmiani; Andrea Anichini
Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients.
International journal of cancer. Journal international du cancer 1994;58(3):330-9.
1994: Antonio Silvani; Andrea Salmaggi; Giorgio Parmiani; Amerigo Boiardi
Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report.
Neurosurgery 1994;34(6):1078-80; discussion 1080-1.
1994: Monica Rodolfo; Chiara Castelli; C Bassi; Paola Accornero; Marialuisa Sensi; Giorgio Parmiani
Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors.
International journal of cancer. Journal international du cancer 1994;57(3):440-7.
1994: C Maccalli; Roberta Mortarini; Giorgio Parmiani; Andrea Anichini
Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
International journal of cancer. Journal international du cancer 1994;57(1):56-62.
1994: S Mattei; Mario P Colombo; Cecilia Melani; Antonio Silvani; Giorgio Parmiani; M Herlyn
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes.
International journal of cancer. Journal international du cancer 1994;56(6):853-7.
1994: Cecilia Melani; Claudia Chiodoni; Flavio Arienti; C Maccalli; J Sule-Suso; Andrea Anichini; Mario P Colombo; Giorgio Parmiani
Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells.
Natural immunity 1994;13(2-3):76-84.
1994: Raffaella Lupetti; Marialuisa Sensi; Roberta Mortarini; Andrea Anichini; Claudio Clemente; Giorgio Parmiani
N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma.
Melanoma research 1994;4(1):11-9.
1993: Cecilia Melani; Antonio Silvani; Giorgio Parmiani; Mario P Colombo
Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA.
FEBS letters 1993;335(1):114-8.
1993: Giorgio Parmiani
Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells.
Immunology today 1993;14(11):536-8.
1993: Marialuisa Sensi; S Salvi; Chiara Castelli; C Maccalli; Arabella Mazzocchi; Roberta Mortarini; Gabriella Nicolini; M Herlyn; Giorgio Parmiani; Andrea Anichini
T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
The Journal of experimental medicine 1993;178(4):1231-46.
1993: Said Dermime; Francesco Grignani; M Clerici; C Nervi; G Sozzi; G P Talamo; Edoardo Marchesi; Franca Formelli; Giorgio Parmiani; P G Pelicci
Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein.
Blood 1993;82(5):1573-7.
1993: Andrea Anichini; Roberta Mortarini; Giorgio Parmiani
The role of cytokines in the modulation of cell surface antigens of human melanoma.
The International journal of biological markers 1993;8(3):151-4.
1993: Antonella Stoppacciaro; Cecilia Melani; Mariella Parenza; A Mastracchio; C Bassi; C Baroni; Giorgio Parmiani; Mario P Colombo
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.
The Journal of experimental medicine 1993;178(1):151-61.
1993: P A Ruffini; Licia Rivoltini; Antonio Silvani; Amerigo Boiardi; Giorgio Parmiani
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.
Cancer immunology, immunotherapy : CII 1993;36(6):409-16.
1993: Cecilia Melani; Gianfranco Mattia; Antonio Silvani; Alessandra Carè; Licia Rivoltini; Giorgio Parmiani; Mario P Colombo
Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes.
Blood 1993;81(10):2744-9.
1993: Licia Rivoltini; V Viggiano; S Spinazzè; A Santoro; Mario P Colombo; K Takatsu; Giorgio Parmiani
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5.
International journal of cancer. Journal international du cancer 1993;54(1):8-15.
1993: Andrea Anichini; C Maccalli; Roberta Mortarini; S Salvi; Arabella Mazzocchi; Paola Squarcina; M Herlyn; Giorgio Parmiani
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
The Journal of experimental medicine 1993;177(4):989-98.
1993: Andrea Anichini; Roberta Mortarini; Saverio Alberti; A Mantovani; Giorgio Parmiani
T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis.
International journal of cancer. Journal international du cancer 1993;53(6):994-1001.
1993: Carlo Gambacorti-Passerini; Francesco Grignani; Flavio Arienti; Pier Paolo Pandolfi; P G Pelicci; Giorgio Parmiani
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.
Blood 1993;81(5):1369-75.
1993: M Vagliani; Cecilia Melani; Giorgio Parmiani; P D'Eustachio; P J Wettstein; Mario P Colombo
Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1).
Immunogenetics 1993;38(2):157-60.
1992: Filiberto Belli; Flavio Arienti; Licia Rivoltini; mario santinami; Luigi Mascheroni; A Prada; M Ammatuna; Edoardo Marchesi; Giorgio Parmiani; Natale Cascinelli
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
Melanoma research 1992;2(4):263-71.
1992: Marialuisa Sensi; Chiara Castelli; S Salvi; Arabella Mazzocchi; Roberta Mortarini; Gabriella Nicolini; Andrea Anichini; Giorgio Parmiani
Expansion of major histocompatibility complex-restricted antimelanoma cytotoxic T-cell lymphocyte clones with identical T-cell receptor from tumor-infiltrating lymphocytes.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):207-11.
1992: Andrea Anichini; Roberta Mortarini; Giorgio Parmiani
Beta 1-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):183-6.
1992: Mario P Colombo; A Modesti; Giorgio Parmiani; G Forni
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.
Cancer research 1992;52(18):4853-7.
1992: Mario P Colombo; C Maccalli; S Mattei; Cecilia Melani; Marina Radrizzani; Giorgio Parmiani
Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines.
Melanoma research 1992;2(3):181-9.
1992: Roberta Mortarini; A Gismondi; A Santoni; Giorgio Parmiani; Andrea Anichini
Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin.
Cancer research 1992;52(16):4499-506.
1992: Giorgio Parmiani; Andrea Anichini; G Carbone; Marialuisa Sensi
Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy?
Melanoma research 1992;2(2):123-5.
1992: Licia Rivoltini; G Cattoretti; Flavio Arienti; A Mastroianni; Giorgio Parmiani
CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytes.
The International journal of biological markers 1992;7(3):143-7.
1992: Mario P Colombo; L Lombardi; Antonella Stoppacciaro; Cecilia Melani; Mariella Parenza; B Bottazzi; Giorgio Parmiani
Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(1):113-9.
1992: Marialuisa Sensi; M Bergomi; P Panceri; Chiara Castelli; Raffaella Lupetti; Catia Traversari; G Carbone; Giorgio Parmiani
Involvement of somatically acquired ecotropic viruses in the immunogenicity of nude-transplanted NIH/3T3 transformed cell lines.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(1):277-83.
1992: Flavio Arienti; Carlo Gambacorti-Passerini; L Borin; Licia Rivoltini; A Orazi; E M Pogliani; Gianmarco Corneo; Giorgio Parmiani
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(2):155-62.
1992: Mario P Colombo; S Mattei; Giorgio Parmiani
Cytokine gene transfer in tumor cells as an approach to antitumor therapy.
International journal of clinical & laboratory research 1992;21(4):278-82.
1992: Licia Rivoltini; Flavio Arienti; A Orazi; Graziella Cefalo; M Gasparini; Carlo Gambacorti-Passerini; Franca Fossati-Bellani; Giorgio Parmiani
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
Cancer immunology, immunotherapy : CII 1992;34(4):241-51.
1991: Marina Radrizzani; B Benedetti; Chiara Castelli; A Longo; G B Ferrara; M Herlyn; Giorgio Parmiani; G Fossati
Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions.
International journal of cancer. Journal international du cancer 1991;49(6):823-30.
1991: Marialuisa Sensi; Chiara Castelli; Andrea Anichini; D Grossberger; Arabella Mazzocchi; Roberta Mortarini; Giorgio Parmiani
Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR V alpha and V beta gene families.
Melanoma research 1991;1(4):261-71.
1991: Arabella Mazzocchi; Monica Rodolfo; Giorgio Parmiani; Andrea Anichini
An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis.
Melanoma research 1991;1(3):169-76.
1991: Cecilia Melani; Licia Rivoltini; Giorgio Parmiani; B Calabretta; Mario P Colombo
Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.
Cancer research 1991;51(11):2897-901.
1991: Mario P Colombo; G Ferrari; Antonella Stoppacciaro; Mariella Parenza; Monica Rodolfo; F Mavilio; Giorgio Parmiani
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.
The Journal of experimental medicine 1991;173(4):889-97.
1991: Licia Rivoltini; G Cattoretti; Flavio Arienti; A Mastroianni; Cecilia Melani; Mario P Colombo; Giorgio Parmiani
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.
International journal of cancer. Journal international du cancer 1991;47(5):746-54.
1991: G Carbone; Maria Grazia Borrello; A Molla; Maria Grazia Rizzetti; Marco A Pierotti; G Della Porta; Giorgio Parmiani
Activation of ras oncogenes and expression of tumor-specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas.
International journal of cancer. Journal international du cancer 1991;47(4):619-25.
1991: Roberta Mortarini; Andrea Anichini; Giorgio Parmiani
Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins.
International journal of cancer. Journal international du cancer 1991;47(4):551-9.
1991: Chiara Castelli; Marialuisa Sensi; Giorgio Parmiani
Recombinant interferon-gamma differently affects DQA and DRA gene expression in two human melanoma clones: transcriptional and posttranscriptional regulation.
Experimental and clinical immunogenetics 1991;8(1):38-48.
1991: Mario P Colombo; G Ferrari; G Biondi; D Galasso; C C Howe; Giorgio Parmiani
Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts.
European journal of cancer (Oxford, England : 1990) 1991;27(1):58-62.
1991: Monica Rodolfo; C Salvi; C Bassi; G Rovetta; Cecilia Melani; Mario P Colombo; Giorgio Parmiani
Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
Natural immunity and cell growth regulation 1991;10(6):308-19.
1991: Monica Rodolfo; C Bassi; C Salvi; Giorgio Parmiani
Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.
Cancer immunology, immunotherapy : CII 1991;34(1):53-62.
1990: M Squadrelli-Saraceno; Licia Rivoltini; Giulio Cantù; Fernando Ravagnani; Giorgio Parmiani; Roberto Molinari
Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.
Tumori 1990;76(6):566-71.
1990: Marialuisa Sensi; M Bergomi; F Formelli; Giorgio Parmiani
Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
International journal of cancer. Journal international du cancer 1990;46(6):1088-94.
1990: Licia Rivoltini; Mario P Colombo; Rosanna Supino; D Ballinari; T Tsuruo; Giorgio Parmiani
Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line.
International journal of cancer. Journal international du cancer 1990;46(4):727-32.
1990: Andrea Anichini; Roberta Mortarini; Rosanna Supino; Giorgio Parmiani
Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability.
International journal of cancer. Journal international du cancer 1990;46(3):508-15.
1990: Licia Rivoltini; Carlo Gambacorti-Passerini; M Squadrelli-Saraceno; M I Grosso; Giulio Cantù; Roberto Molinari; A Orazi; Giorgio Parmiani
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Cancer research 1990;50(17):5551-7.
1990: L Munari; Antonio Silvani; C G Passerini; Marina Radrizzani; Giorgio Parmiani; Amerigo Boiardi
Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
Journal of neurosurgical sciences 1990;34(3-4):283-8.
1990: Andrea Anichini; Roberta Mortarini; E Berti; Giorgio Parmiani
Multiple VLA antigens on a subset of melanoma clones.
Human immunology 1990;28(2):119-22.
1990: Giorgio Parmiani
An explanation of the variable clinical response to interleukin 2 and LAK cells.
Immunology today 1990;11(4):113-5.
1990: Giorgio Parmiani; Andrea Anichini; G Fossati
Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?
Journal of the National Cancer Institute 1990;82(5):361-70.
1990: Roberta Mortarini; Filiberto Belli; Giorgio Parmiani; Andrea Anichini
Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations.
International journal of cancer. Journal international du cancer 1990;45(2):334-41.
1990: Chiara Castelli; F Mazzucchelli; Marialuisa Sensi; G Carbone; Giorgio Parmiani
H-2 class I gene analysis in 3-methylcholanthrene-induced murine fibrosarcomas.
Experimental and clinical immunogenetics 1990;7(2):129-35.
1990: Marialuisa Sensi; L Grazioli; Monica Rodolfo; Giorgio Parmiani
Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.
Cancer immunology, immunotherapy : CII 1990;31(1):37-43.
1990: Monica Rodolfo; C Salvi; C Bassi; Giorgio Parmiani
Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Cancer immunology, immunotherapy : CII 1990;31(1):28-36.
1990: Arabella Mazzocchi; Andrea Anichini; Chiara Castelli; Marialuisa Sensi; F Poli; C Russo; Giorgio Parmiani
T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone.
Cancer immunology, immunotherapy : CII 1990;32(1):13-21.
1990: Monica Rodolfo; C Salvi; C Bassi; Marialuisa Sensi; Giorgio Parmiani
Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
Annali dell'Istituto superiore di sanità 1990;26(3-4):423-32.
1989: Mario P Colombo; P Baracetti; G Cairo; C Schneider; Giorgio Parmiani
A TaqI RFLP at the gas-2 locus.
Nucleic acids research 1989;17(18):7545.
1989: Carlo Gambacorti-Passerini; Licia Rivoltini; Marina Radrizzani; Filiberto Belli; Gianalfredo Sciorelli; Fernando Ravagnani; A R Galazka; Natale Cascinelli; Giorgio Parmiani
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Cancer research 1989;49(18):5230-4.
1989: Chiara Castelli; F Mazzucchelli; Marialuisa Sensi; G Fossati; Giorgio Parmiani
Loss of heterozygosity of DQ alpha gene in human malignant melanoma.
Tumori 1989;75(4):378-82.
1989: Natale Cascinelli; Filiberto Belli; S Marchini; R Marolda; A Prada; Gianalfredo Sciorelli; F Villani; Carlo Gambacorti-Passerini; A Galazka; Giorgio Parmiani
A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
Tumori 1989;75(3):233-44.
1989: Licia Rivoltini; Carlo Gambacorti-Passerini; Rosanna Supino; Giorgio Parmiani
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
International journal of cancer. Journal international du cancer 1989;43(5):880-5.
1989: Andrea Anichini; Arabella Mazzocchi; G Fossati; Giorgio Parmiani
Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(10):3692-701.
1989: Catia Traversari; G Carbone; Gabriella Della Torre; M Bergomi; Giorgio Parmiani; Marialuisa Sensi
Expression of retrovirus-related, cytotoxic T lymphocyte- and transplantation-defined antigens in NIH/3T3 transfectants after a single passage in nude mice.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(8):2887-94.
1989: Monica Rodolfo; C Salvi; Giorgio Parmiani
Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
Cancer immunology, immunotherapy : CII 1989;28(2):136-42.
1989: Giorgio Parmiani; Licia Rivoltini
In vitro lymphocyte response to autologous melanoma: clues in designing new adoptive immunotherapy protocols.
European journal of cancer & clinical oncology 1989;25 Suppl 3():S37-9.
1989: Mario P Colombo; G Biondi; D Galasso; P Baracetti; C C Howe; Giorgio Parmiani
Osteonectin transcript and metastatic behavior in v-Ki-ras transformed fibroblasts.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1989;4():76-7.
1989: Marina Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; Enzo Galligioni; G Fossati; Giorgio Parmiani
Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.
Cancer immunology, immunotherapy : CII 1989;30(4):233-8.
1989: Marina Radrizzani; Carlo Gambacorti-Passerini; Giorgio Parmiani; G Fossati
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.
Cancer immunology, immunotherapy : CII 1989;28(1):67-73.
1988: Carlo Gambacorti-Passerini; Licia Rivoltini; Marina Radrizzani; Rosanna Supino; M Mariani; Giorgio Parmiani
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).
Cancer metastasis reviews 1988;7(4):335-45.
1988: Carlo Gambacorti-Passerini; Marina Radrizzani; Licia Rivoltini; Edoardo Marchesi; Fernando Ravagnani; Gianalfredo Sciorelli; Natale Cascinelli; Giorgio Parmiani
A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancer.
Tumori 1988;74(5):523-30.
1988: Carlo Gambacorti-Passerini; Licia Rivoltini; Rosanna Supino; M Mariani; Giorgio Parmiani
Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx).
International journal of cancer. Journal international du cancer 1988;42(4):544-8.
1988: Mario P Colombo; D Galasso; G Ferrari; Giorgio Parmiani
Strain polymorphism and tentative mapping of mouse ornithine decarboxylase.
Nucleic acids research 1988;16(18):9075.
1988: G Fossati; Andrea Anichini; Paola Squarcina; Arabella Mazzocchi; Giorgio Parmiani
Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma.
International journal of cancer. Journal international du cancer 1988;42(2):239-45.
1988: Carlo Gambacorti-Passerini; Marina Radrizzani; R Marolda; Filiberto Belli; Gianalfredo Sciorelli; A R Galazka; J D Schindler; Natale Cascinelli; Giorgio Parmiani
In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.
International journal of cancer. Journal international du cancer 1988;41(5):700-6.
1988: Carlo Gambacorti-Passerini; Licia Rivoltini; Rosanna Supino; Monica Rodolfo; Marina Radrizzani; G Fossati; Giorgio Parmiani
Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
Cancer research 1988;48(9):2372-6.
1988: D Taramelli; A Mazzocchi; C Clemente; G Fossati; Giorgio Parmiani
Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.
Cancer immunology, immunotherapy : CII 1988;26(1):61-6.
1988: G Fossati; Andrea Anichini; Arabella Mazzocchi; Paola Squarcina; Giorgio Parmiani
Reactivity of human lymphocyte clones to autologous metastatic melanoma cells.
Advances in experimental medicine and biology 1988;233():73-80.
1988: Giorgio Parmiani; G Fossati; Marina Radrizzani; Carlo Gambacorti-Passerini; R Marolda; Natale Cascinelli
Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes.
Advances in experimental medicine and biology 1988;233():453-8.
1988: Monica Rodolfo; A Balsari; C Clemente; Giorgio Parmiani; G Fossati
Tumorigenicity and dissemination of primary and metastatic human melanomas implanted into different sites in athymic nude mice.
Invasion & metastasis 1988;8(6):317-31.
1988: Andrea Anichini; Chiara Castelli; G Sozzi; G Fossati; Giorgio Parmiani
Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(1):183-91.
1987: R Marolda; Filiberto Belli; A Prada; F Villani; Carlo Gambacorti-Passerini; A Galazka; Giorgio Parmiani; Natale Cascinelli
A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects.
Tumori 1987;73(6):575-84.
1987: Giorgio Parmiani; L Grazioli; Marialuisa Sensi; M P Colombo; Monica Rodolfo
Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes.
Biochimica et biophysica acta 1987;907(2):163-74.
1987: Carlo Gambacorti-Passerini; Marina Radrizzani; E Erba; G Fossati; Giorgio Parmiani
Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide.
Cancer research 1987;47(10):2547-52.
1987: Catia Traversari; G Ferrari; L Grazioli; D Ballinari; M P Colombo; Chiara Castelli; Marco A Pierotti; Giorgio Parmiani
Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity.
Experimental and clinical immunogenetics 1987;4(2):106-14.
1987: L Grazioli; Marialuisa Sensi; Giorgio Parmiani
Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma.
Cancer immunology, immunotherapy : CII 1987;24(3):237-43.
1986: G Fossati; Andrea Anichini; D Taramelli; A Balsari; C Gambacorti-Passerini; J M Kirkwood; Giorgio Parmiani
Immune response to autologous human melanoma: implication of class I and II MHC products.
Biochimica et biophysica acta 1986;865(3):235-51.
1986: A Balsari; G Tona; M P Colombo; G Fossati; Giorgio Parmiani
Control of human melanoma growth in nude mice by autologous allo-activated peripheral blood lymphocytes.
International journal of cancer. Journal international du cancer 1986;38(6):923-7.
1986: Carlo Gambacorti-Passerini; R Marolda; G Tona; Gianalfredo Sciorelli; G Fossati; Natale Cascinelli; Giorgio Parmiani
Infusion of autologous alloactivated lymphocytes in melanoma patients: toxicity and immunologic monitoring.
Tumori 1986;72(4):383-8.
1986: Giorgio Parmiani; D Taramelli; Andrea Anichini; S Andreola; N Cascinelli; G Fossati
Phenotypic heterogeneity of HLA products on human melanoma cells.
Journal of immunogenetics 1986;13(2-3):235-40.
1986: Marialuisa Sensi; L Grazioli; Giorgio Parmiani
Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells.
Cancer immunology, immunotherapy : CII 1986;21(3):199-204.
1986: A Balsari; R Marolda; Carlo Gambacorti-Passerini; Gianalfredo Sciorelli; G Tona; E Cosulich; D Taramelli; G Fossati; Giorgio Parmiani; Natale Cascinelli
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.
Cancer immunology, immunotherapy : CII 1986;21(2):148-55.
1986: Giorgio Parmiani; Marialuisa Sensi; A Balsari; M P Colombo; Carlo Gambacorti-Passerini; L Grazioli; Monica Rodolfo; Natale Cascinelli; G Fossati
Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studies.
La Ricerca in clinica e in laboratorio 1986;16(1):1-20.
1985: D Ballinari; L Grazioli; Marialuisa Sensi; Maria Grazia Borrello; Giorgio Parmiani
DBA/2-like minor histocompatibility antigens on a BALB/c lymphoma. A BALB/c anti-DBA/2 serum which lyses the tumor and blocks BALB/c anti-tumor and anti-DBA/2 effectors.
International journal of cancer. Journal international du cancer 1985;36(5):617-22.
1985: G Carbone; Marco A Pierotti; M Boiocchi; A B De Leo; D Ballinari; Paolo Radice; Maria Grazia Borrello; A Meseguer; A Cernuschi; Giorgio Parmiani
Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virus.
Cancer research 1985;45(10):4980-5.
1985: D Ballinari; Chiara Castelli; Catia Traversari; M A Pierotti; Giorgio Parmiani; G Palmieri; P Ricciardi-Castagnoli; L Adorini
Disulfide-linked surface molecules of monoclonal antigen-specific suppressor T cells: evidence for T cell receptor structures.
European journal of immunology 1985;15(8):855-60.
1985: A Balsari; G Fossati; D Taramelli; G Tona; D Delia; R Giardini; Giorgio Parmiani
Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma.
British journal of cancer 1985;52(1):73-80.
1985: Giorgio Parmiani; G Fossati; D Taramelli; Andrea Anichini; A Balsari; Carlo Gambacorti-Passerini; Gianalfredo Sciorelli; N Cascinelli
Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.
Cancer metastasis reviews 1985;4(1):7-26.
1984: D Taramelli; G Fossati; A Balsari; R Marolda; Giorgio Parmiani
The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.
International journal of cancer. Journal international du cancer 1984;34(6):797-806.
1984: G Fossati; D Taramelli; A Balsari; G Bogdanovich; S Andreola; Giorgio Parmiani
Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes.
International journal of cancer. Journal international du cancer 1984;33(5):591-7.
1984: A Balsari; G Fossati; D Taramelli; M Nava; F Ravagnani; Giorgio Parmiani
Inhibition of human melanoma growth in nude mice by autologous, alloactivated peripheral blood lymphocytes.
Tumori 1984;70(1):35-9.
1984: Marco A Pierotti; Catia Traversari; D Ballinari; Maria Grazia Borrello; Giorgio Parmiani
Ly-5 molecular forms in congenitally immunodeficient mice.
Experimental and clinical immunogenetics 1984;1(2):75-82.
1983: Marco A Pierotti; D Ballinari; M P Colombo; L Grazioli; Giorgio Parmiani
Role of the carbohydrate prosthetic groups in the biosynthesis of membrane antigens and in the H-2-restricted lysis of MBL-2 lymphoma cells.
Transplantation proceedings 1983;15(4):2068-73.
1983: G Carbone; M P Colombo; Marialuisa Sensi; A Cernuschi; Giorgio Parmiani
In vitro detection of cell-mediated immunity to individual tumor-specific antigens of chemically induced BALB/c fibrosarcomas.
International journal of cancer. Journal international du cancer 1983;31(4):483-9.
1983: D Ballinari; Marco A Pierotti; Marialuisa Sensi; Giorgio Parmiani
Lack of H-2Ld locus products on a BALB/c fibrosarcoma expressing H-2k-like alien antigens.
Journal of immunogenetics 1983;10(2):115-25.
1982: D Ballinari; Marco A Pierotti; L Grazioli; M Cattaneo; M J Rogers; Giorgio Parmiani
Biochemical analysis of a public H-2 specificity revealed by an anomalous reaction of an alloantiserum with a chemically induced C57BL/10 fibrosarcoma.
Journal of immunogenetics 1982;9(4):267-75.
1982: Giorgio Parmiani; Marialuisa Sensi; G Carbone; M Colombo; Marco A Pierotti; D Ballinari; J Hilgers; J Hilkens
Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
International journal of cancer. Journal international du cancer 1982;29(3):323-32.
1982: G Fossati; A Balsari; D Taramelli; Marialuisa Sensi; G Pellegris; M Nava; Giorgio Parmiani
Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.
Cancer immunology, immunotherapy : CII 1982;14(2):99-104.
1981: M J Rogers; G Carbone; D Ballinari; M Cattaneo; Giorgio Parmiani
Biochemical characterization of the anomalous reaction of anti-H-2b alloantiserum with a chemically induced sarcoma of H-2k origin.
Transplantation proceedings 1981;13(4):1774-81.
1980: Giorgio Parmiani; D Ballinari; Marialuisa Sensi
Tumor-associated alien alloantigens of BALB/c tumors encoded by the MHC and by non-H-2 genes: a histogenetic study.
Journal of immunology (Baltimore, Md. : 1950) 1980;124(2):662-8.
1978: Giorgio Parmiani
Genetic control of responsiveness to the tumor-associated transplantation antigen of a chemically induced murine fibrosarcoma.
Immunogenetics 1978;7(1):271-5.